Pfizer (NYSE:PFE) Shares Sold Off Sen. Tommy Tuberville

Senator Tommy Tuberville (Republican-Alabama) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on July 16th, the Senator disclosed that they had sold between $15,001 and $50,000 in Pfizer stock on June 8th.

Senator Tommy Tuberville also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 6/9/2026.
• Sold $15,001 – $50,000 in shares of American Water Works (NYSE:AWK) on 6/8/2026.
• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 6/8/2026.
• Sold $15,001 – $50,000 in shares of Duke Energy (NYSE:DUK) on 6/8/2026.
• Sold $15,001 – $50,000 in shares of Lockheed Martin (NYSE:LMT) on 6/8/2026.
• Sold $15,001 – $50,000 in shares of Mastercard (NYSE:MA) on 6/8/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 6/8/2026.
• Sold $15,001 – $50,000 in shares of Procter & Gamble (NYSE:PG) on 6/8/2026.
• Sold $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 6/8/2026.

Pfizer Stock Performance

Pfizer stock traded down $0.06 during trading hours on Friday, hitting $25.08. The stock had a trading volume of 45,600,737 shares, compared to its average volume of 45,182,364. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $25.21 and a two-hundred day moving average of $26.17. The company has a market cap of $142.94 billion, a PE ratio of 19.15 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm earned $0.92 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. Guggenheim cut their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, UBS Group restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.50.

Institutional Trading of Pfizer

Several hedge funds have recently modified their holdings of the stock. Horizon Financial Services LLC lifted its stake in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the 4th quarter worth about $26,000. Keb Asset Management LLC acquired a new position in Pfizer during the 2nd quarter valued at about $26,000. YANKCOM Partnership bought a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Finally, HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech…

About Senator Tuberville

Tommy Tuberville (Republican Party) (also known as Coach) is a member of the U.S. Senate from Alabama. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Tuberville (Republican Party) ran for election to the U.S. Senate to represent Alabama. He won in the general election on November 3, 2020. Tuberville was head coach for several college football teams between 1995 and 2016, including at Auburn University and the University of Cincinnati. Tommy Tuberville was born in Camden, Arkansas, and lives in Auburn, Alabama. Tuberville’s career experience includes working as a studio analyst with ESPN and as the head football coach of the University of Mississippi, the University of Auburn, Texas Tech University, and the University of Cincinnati.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.